首页> 外文期刊>Case Reports in Hematology >Successful Treatment of Mild Pediatric Kasabach-Merritt Phenomenon with Propranolol Monotherapy
【24h】

Successful Treatment of Mild Pediatric Kasabach-Merritt Phenomenon with Propranolol Monotherapy

机译:普萘洛尔单药治疗成功治疗轻度小儿卡萨巴赫-梅里特现象

获取原文
           

摘要

Kasabach-Merritt phenomenon (KMP) is relatively rare in childhood and adolescents with high mortality rate because of its hemorrhagic complications and unresponsiveness to treatments such as corticosteroids, vincristine, intravascular embolization, and/or surgery. Propranolol, aβ-adrenergic receptor blocker, has a promising efficacy against vascular tumors such as infantile hemangiomas. But limited and variable data has been reported regarding the role of propranolol in treatment of KMP. We herein reported the successful treatment of mild pediatric KMP with propranolol monotherapy in a case of a five-week-old child with kaposiform hemangioendothelioma with successful treatment of both clinical and hematologic responses. After eight months of follow-up, patient still had stable cutaneous lesion while receiving propranolol monotherapy. Regular hematologic monitoring was done in order to detect any late relapse of the disease. Six months after discontinuation of propranolol, patient has still remained free of hematologic relapse, and primary cutaneous lesion has become a pale pink, 1 cm sized skin lesion.
机译:Kasabach-Merritt现象(KMP)在具有高死亡率的儿童和青少年中相对罕见,因为它具有出血并发症和对皮质类固醇,长春新碱,血管内栓塞和/或手术等治疗方法无反应。普萘洛尔,一种β-肾上腺素受体阻滞剂,对血管性肿瘤如婴儿血管瘤具有有效的疗效。但是,关于普萘洛尔在治疗KMP中的作用的报道有限而可变。我们在本文中报道了在一个五周大的卡波西型血管内皮瘤患者中,使用心得安单药成功治疗了轻度儿科KMP,并成功治疗了临床和血液学反应。八个月的随访后,患者在接受普萘洛尔单药治疗时仍具有稳定的皮肤病变。定期进行血液学监测,以发现该病的任何晚期复发。普萘洛尔停药六个月后,患者仍无血液学复发,原发性皮肤病变已变成浅粉红色,1 cm大小的皮肤病变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号